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b“If I had an enemy, I would teach him angioplasty”
Andreas Gruentzig, MD, 1980
(Richard Myler, MD,
personal communication, June 1984)
he words of Andreas Gruentzig reflect the emotional
nguish and uncertainty that accompanied inflation of a
uid-filled balloon in a human coronary artery. Abrupt
oronary occlusion complicated 4% to 8% of balloon angio-
lasty procedures, was largely unpredictable, and was asso-
iated with considerable morbidity and mortality for the
atient (1–3). By scaffolding balloon-mediated plaque dis-
uption and facilitating laminar flow, stents provide a more
redictable immediate angiographic result and reduce the
isk of procedural complications. Furthermore, multiple
andomized comparative trials of coronary balloon angio-
lasty versus stenting have demonstrated a salutary effect of
tents on late (6 months) coronary reocclusion/restenosis
4–8). Nevertheless, clinical and/or angiographic restenosis
fter conventional stent deployment still occurs in a sub-
tantial portion of patients and often necessitates repeat
evascularization procedures. The cumulative societal bur-
en of coronary restenosis on global health care expendi-
ures and quality of life was considerable in the era of
onventional stents. More recently, targeted polymer-based
lution of both sirolimus (a cytostatic macrocyclic lactone
ith anti-inflammatory and antiproliferative properties) and
aclitaxel (a lipophilic derivative of the TAXUS Brevifolia
ree capable of inhibiting the cellular processes of mitosis,
otility, secretion, and signal transduction) from stent
latforms have dramatically reduced the neointimal prolif-
rative response to stent-vessel injury and, thus, have re-
uced the occurrence and cost of restenosis (9–11). These
ovel devices have rapidly transformed the practice of
ercutaneous coronary intervention (PCI). Recent estimates
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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ohnson & Johnson.uggest that in the U.S. 85% of coronary stents currently
eployed are drug-eluting stents. Application of drug-
luting stents to the remaining 15% of patients undergo-
ng PCI is limited only by a lack of available U.S. Food and
rug Administration (FDA)-approved stent sizes (2.5
nd 4.0 mm diameter) and/or difficulties in deliverability
f the current drug-eluting stent platforms.
Although the two available drug-eluting stents (TAXUS–
aclitaxel-eluting [Boston Scientific, Natick, Massachu-
etts] and Cypher–sirolimus-eluting [Cordis Corp., Miami
akes, Florida]) differ considerably in metal platform de-
ign, polymer, and active pharmacologic agent, their use
ay be perceived as interchangeable by interventional car-
iologists in a manner analogous to “therapeutic substitu-
ion” and the concept of “class effect” as frequently applied
o pharmacotherapies. To what degree these assumptions
re correct and how far presumed “class effects” may apply to
ew drug-eluting stents platforms is unknown. The contri-
utions from six substudies of the pivotal TAXUS-IV trial
f the TAXUS stent, which appear in this issue of the
ournal (12–17), provide perspectives on this new technol-
gy as well as the opportunity for reflection on clinical trial
esign, analysis, and application to clinical practice. Let us
rst examine the fundamental concepts raised by Ellis et al.
12) regarding the quantitative angiographic end point
easure of late coronary lumen loss and its relationship to
linical events.
ATE LOSS, STATISTICS, AND INFERENCE
he measurement of the magnitude of re-narrowing at late
six- to nine-month) follow-up has been a valuable method
o gauge the need for repeat intervention of the target lesion
18,19), and to elucidate the mechanism of re-narrowing
elt to be predominantly due to intimal hyperplasia within
nd just outside the stent boundaries (20). The metrics
mployed to measure this magnitude include the continuous
nd statistically powerful end points of percent diameter
tenosis, late loss in lumen diameter (measured in millime-
ers), and intimal volume, measured as an absolute or
elative volume by intravascular ultrasound (reported in this
ssue by Weissman et al. [17]). The notion that all fixed
alloon-expanded metal stents undergo some level of re-
arrowing, summarized as the mean in-stent (or in-
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April 19, 2005:1206–12 Editorial Commentegment) late lumen loss, and that excessive re-narrowing in
minority leads to flow limitation and the need for repeat
ntervention, summarized as target lesion (or target vessel)
evascularization rate, supports the utility of reporting the
ean late lumen loss as a surrogate for binary clinical
estenosis propensity. While multiple bare-metal stent trials
ave demonstrated an average late loss (in-stent) of approx-
mately 0.8 to 1.0 mm with corresponding clinical restenosis
target lesion revascularization [TLR]) rates of approxi-
ately 15% to 25%, recent successful drug-eluting stent
rials have demonstrated a clear beneficial treatment effect
videnced by low mean in-stent late losses of 0.2 to 0.4 mm
ccompanied by low clinical restenosis (TLR) rates of 5% to
%. Moreover, the continuous and near normal distribution
f late loss (21,22) allows the assumption of monotonicity in
he relationship between incremental higher mean late loss
alues (for any given stent or patient cohort) and higher
robabilities of excessive re-narrowing causing binary clin-
cal restenosis.
Ellis et al. (12) challenge this expected correlative rela-
ionship between late loss and clinical restenosis. Over the
.0 to 1.0 mm range of average late loss values seen in the
ide spectrum of bare-metal and drug-eluting stent trials,
he authors propose that any stents with average late losses
f up to 0.5 to 0.65 mm (in-segment) and 0.75 to 1.0 mm
in-stent) have a low and relatively flat relationship to the
isk of restenosis. They propose that stents with mean late
oss values below these thresholds have equivalent low
linical restenosis potentials, with no practical discriminat-
ng value for differences in average late loss. The basis of
heir conclusion is derived from an analysis of the relation-
hip between late loss and TLR for individual patients from
he TAXUS-IV trial (10). However, neither this analysis
or their conclusion is appropriate for a discussion of the
elationship between average late loss values of stents and
he probability of clinical restenosis. The authors motivate
heir analysis of late loss in the TAXUS-IV trial by stating
hat the interrelationship between late loss, binary resteno-
is, and TLR after bare-metal stenting has not been com-
letely evaluated. The tautology of the interrelationship
etween these variables in patients probably explains the lack
f prior formal analysis. For any patient who receives a stent,
he interrelationship between late loss and binary restenosis
defined as 50% diameter stenosis), for example, is essen-
ially defined by a simple arithmetic formula. For a 3.0-mm
oronary artery, the usual acute result (from virtually all
ontemporary balloon-expandable stent trials) is an average
% residual in-stent percent diameter stenosis, or an in-
tent minimum lumen diameter of approximately 2.85 mm.
n order to qualify for binary restenosis (50% diameter
tenosis at follow-up), this lumen will have to be reduced to
1.50 mm, corresponding to a late loss of 1.35 mm.
hus, for a 3.0-mm stented artery, the interrelationship
etween in-stent late loss and binary restenosis is a step
unction. That is, late loss up to 1.35 mm would generally
ot be associated with binary restenosis (because all percent aiameter stenosis possibilities would be below 50%), and
ate loss 1.35 mm would be associated with binary
estenosis (because all possible percent diameter stenosis
ould be 50%). A graph of the relationship between late
oss on the abscissa and the probability of binary restenosis
n the ordinate would essentially be a square step function:
at and 0 up to 1.35 mm, with an immediate inflection at
.35 mm, and flat and 100% above 1.35 mm.
Given that stent trials have variable reference vessel sizes,
f which the vast majority are between 2.5 and 3.2 mm, the
redicted step function of the interrelationship between late
oss and binary restenosis would contain a softer inflection
oint and look less square than in the above 3.0-mm
xample. The inflection, while still step-like in appearance,
ould occur less sharply over the 1.1 to 1.4 mm range of
n-stent late loss. It is no surprise that any patient with an
n-stent late loss below 1.1 mm would have a low probability
f binary restenosis, while any patient with a late loss above
.4 mm would have a high probability of binary restenosis in
he typical reference vessel size range. This result holds true
hether the tested stent is bare-metal or drug-eluting.
If this example is now extended to examine late loss and
LR, the relationship would still be formulaic, predictable,
nd step-like. Target lesion revascularization is generally
djudicated (as described by Ellis et al. [12]) as being
ositive when: 1) the percent diameter stenosis is 70%
ith symptoms; or 2) there is revascularization and clinical
schemia when the percent diameter stenosis is between
0% to 70%. It is generally adjudicated as negative if the
ercent diameter stenosis is below 50%. Although these
ules further soften the inflection point, there remains a
redictable slanted step function that has a flat and near 0
ikelihood of TLR when late loss is below 1.0 mm, and near
00% TLR when late loss is above 1.5 mm.
The study by Ellis et al. (12) confirms this intuition, that
s, there is an inflection point in the fitted logit model of late
oss and TLR at about 1.0 mm for in-stent late loss and 0.6
m for in-segment late loss (which is a softer measure of
ate loss and has a narrower range of values than in-stent late
oss). The authors have reaffirmed this generally well-
ppreciated concept that it takes about 50% or more
e-narrowing, measured by the amount of in-stent or
n-lesion late loss, to drive TLR in a given individual.
However, of greater interest to clinicians is the interrela-
ionship between average late loss (of different stent types or
ifferent patient risk subsets) and the probability of clinical
estenosis. This relationship has direct implications on how
ne might chose a drug-eluting stent for a patient with a
oronary obstruction. One would like to know whether a
tent with an average late loss of 0.17 mm (Cypher stent:
U.S. multicenter, randomized, double-blind study of
he SIRolImUS-eluting stent in de novo native coronary
esions [SIRIUS] [9] trial), or 0.39 mm (TAXUS stent:
AXUS-IV trial [10]), or 0.81 mm (non-polymer paclitaxel
lution ACHIEVE stent [Cook and Guidant Corp., Indi-
napolis, Indiana]: DELIVER trial [23]) have differences in
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Editorial Comment April 19, 2005:1206–12linical restenosis risk. Such an analysis requires one to
stimate the fraction of patients who exceed the already
nown 1.2- to 1.4-mm late loss threshold required for
ndividual TLR, when their expected mean late loss is 0.17,
.39, or 0.81 mm. This interrelationship was not examined
y Ellis et al. (12). Although the authors point out that
robability distributions of late loss are affected by theoret-
cal differences in spread (variance) and skew (right-shift),
hey do not provide an analysis that relates varying mean late
oss values to the density of the zone of the continuous
istribution beyond the threshold where late loss is high and
ssociated with clinical restenosis, as already defined by the
ndividual patient late loss-TLR analysis.
The actual distribution of continuous angiographic reste-
osis metrics has been examined for drug-eluting stents
24,25) and has been shown to be right-skewed when mean
ate loss is low. In fact, the magnitude of right skew is
nversely proportional to the mean until the mean is in the
are-metal stent range of 0.8 to 1.0 mm, where the
istribution is near normal (21,22,24,25). Moreover, late
oss variance estimates are proportional to the late loss
eans over the range from right skew to near normal (25) as
een with similar biological near Gaussian distributions.
ne would assume, therefore, under parametric continuous
robability distribution theory, that the higher the late loss
ean, the higher the likelihood that any patient may
chieve the fixed late loss threshold that is associated with
LR. In other words, the baseline null assumption to be
isproved would be the notion that a family of ordered
istributions with different mean values (such as distribu-
ions of average in-stent late loss from different drug-eluting
tents or at-risk patient cohorts) would be associated with
ncreasing risks of restenosis, defined precisely as the density
f their distribution above some fixed threshold of late loss,
uch as 1.2- to 1.5-mm in-stent late loss. The pivotal
uestion is how much separation in mean values is clinically
mportant, not whether the interrelationship between the
ean and right-sided density is correlated and ordered.
The flat square-like curve reported by Ellis et al. (12),
hich describes the individual patient late loss-TLR inter-
elationship, does not address this latter concern for mean
alues. Although the authors correctly state knowledge of
he population distribution of late loss is also required to
ccurately predict overall late loss, confusion arises in their
iscussion where inferences are made about relating average
ate losses (mean in-stent and in-segment) to the probability
f TLR. The authors conclude that:
“A mean analysis segment late loss of 0.5 mm (or in-stent
late loss of 0.75 mm) after drug-eluting stent implantation
is adequate to achieve TLR rates5%. Greater reduction of
late loss may not translate into significantly lower TLR
rates, because the relatively flat portion of the TLR/late loss
curve has been reached.”
nfortunately, they use the individual patient-based analy-
is and curve to reach conclusions on the average late foss-TLR relationship. The authors quote the similarity in
linical restenosis rates between two trials, SIRIUS and
AXUS-IV, which have corresponding in-stent late loss
ean values of 0.17 and 0.39 mm, respectively, to substan-
iate this claim although the confidence intervals about the
linical restenosis rates from these studies are too wide to
rovide adequate support for equating restenosis risk based
n different late loss values.
Their principal finding, that patients need about 1 mm or
ore of in-stent late loss to have restenosis, is translated
nto a conclusion that stents with average late losses of up to
.5 mm (in-segment) and 0.75 mm (in-stent) have similar
ow risk of restenosis. This is counter-intuitive, because the
ean in-stent late loss observed for Cypher, TAXUS, and
CHIEVE drug-eluting stents as well as their bare-metal
ontrols were all well below or only slightly above this
.75-mm threshold. Despite the closeness between their
roposed 0.75-mm late loss threshold and the average late
oss values reported for many bare-metal stents, the authors
tate that a reduction of 0.2 to 0.4 mm (from bare-metal
.8- to 1.0-mm average in-stent late loss values to the
.75-mm threshold value, below which all stents have the
ame low restenosis rate) would have a marked impact on
educing restenosis. This conclusion would suggest that
any bare-metal stents (with in-stent late loss of 0.75 mm
r lower) already possess drug-eluting stent-like antirest-
nosis properties. Thus, although Ellis et al. (12) have
emonstrated the intuitive relationship between in-stent
ate loss and clinical restenosis for any given patient to be a
tep function with an inflection above 0.75-mm late loss
in-stent), the more practical relationship between average
mean in-stent or in-segment) late loss and clinical reste-
osis (likely not a step function) was not analyzed. The
uthors observed right skewness in the low mean late loss
istribution of a drug-eluting stent, but did not provide
stimates of the probability of reaching the high late loss
hreshold (1.0- to 1.5-mm in-stent late loss) from varying
ean values. A more workable approximation of restenosis
that estimates the actual density of high late loss) for
rug-eluting stents may be derived by employing one of
everal transformation procedures of the late loss distribu-
ion (25). The mean late loss values and the propensity for
igh late loss density beyond a given threshold are corre-
ated, but the minimum difference in late loss means that
as clinical relevance cannot be estimated by such a patient-
ased analysis, and remains unknown.
PIVOTAL” DRUG-ELUTING STENT TRIALS IN
ERSPECTIVE: A LOOK TOWARD THE FUTURE
he TAXUS-IV trial and other pivotal drug-eluting stent
linical trials are inherently limited in inferential capacity by
heir very design. Although they serve as primary evidence for
reakthrough technologies (such as paclitaxel-eluting stents) in
he safe treatment of coronary stenosis, they balance the need
or homogeneity of subjects to allow definitive measure of the
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April 19, 2005:1206–12 Editorial Commentehavior of the investigational device being tested, with the
eed for heterogeneity to allow generalizability. These rela-
ively small and limited (initially) duration follow-up trials
erive valuable mechanistic and safety information from sub-
ecting even asymptomatic patients to invasive evaluations such
s angiography or intravascular ultrasound. Safety concerns
egarding the use of protocol angiography or ultrasound must
arefully balance the insights provided with which to better
rofile rare or late clinical events with the fact that these
nvasive evaluations provide only surrogate measures for real
linical outcomes. For example, the issue of optimal adjust-
ent for skew in angiographic measures raised previously is
ased on a correlation with clinically meaningful events (i.e.,
oronary revascularization).
After U.S. FDA approval of two drug-eluting stent
latforms, newer drug-eluting stent platforms can no longer
e defined by clinical trials (such as TAXUS-IV and
IRIUS), which test superiority versus placebo (i.e., bare-
etal stent controls). Both ethical and practical issues
ictate a shift to active control noninferiority studies, as
either patients nor physicians will support clinical trials
ith clearly inferior treatment arms. Although a shift to
active control” studies with relatively lower clinical event
ates might appear to support the need for surrogate
ngiographic end points in order to make these studies
easible, this perception implies a shift from use of protocol
ngiography primarily for safety concerns to its use instead
s a primary measure of device effectiveness. However, the
ecessity for requiring invasive evaluations in follow-up
ecomes both an ethical and practical question when pa-
ients can be treated with an approved “active control” drug-
luting stent without participating in the research study.
An assumption central to the conclusion that low clinical
vent rates mandate angiographic surrogates for feasible
evice trials deserves scrutiny. Low event rates are driven
ot only by enhanced drug-eluting stent effectiveness, but
lso by the “plain vanilla” low-risk patient selection criteria
ypically used in pre-market pivotal studies. Thus, in both
he TAXUS-IV and SIRIUS trials, patients with single-
essel/single-lesion disease, a relatively low incidence of
iabetes, and a virtual absence of comorbidities contributed
o the low overall event rates observed. Modification of
ubject enrollment criteria could dramatically influence the
easibility for measuring “real” clinical end points in trials
nd reduce the dependence on surrogate angiographic
easures. For example, a robust approach for understanding
new drug-eluting stent platform that could also provide
linicians and regulatory authorities with valuable prospec-
ive data on an already approved drug-eluting stent device
ould be to enroll a more complex patient population than
as studied in prior pivotal superiority trials. This “enriched
opulation” could step beyond the historical pre-market
tudy population by: 1) increasing the density of clinical end
oints and thus promoting feasible trials based on real
utcomes measures; 2) being more reflective of post-market
real world” use, so that data obtained in the pre-market ttudy should be more predictive of actual post-market risk
nd benefit; 3) more closely approximating patients treated
n clinical practice so that enthusiasm of physicians to
ecruit patients and for patients to enroll in clinical research
hould be enhanced; and 4) being an exploratory population
o that statistical analysis plans would uniquely accommo-
ate for unknowns in both the active control and treatment
rms for determination of noninferiority.
One example of an enriched population would be the
nclusion of patients with multivessel disease, which should
nclude a higher proportion of diabetics and could promote
clinical event density rate sufficient to support a feasible
tudy of real clinical end points.
The need for angiographic information and “invasive
isk” for patients who participate in an enriched population
tudy could be more specifically tailored to the novelty of the
rug-eluting stent platform per se.
CTIVE CONTROL STUDIES:
HE VALUE OF THE IMPUTED PLACEBO
wo issues to be addressed for active control clinical trials of
rug-eluting stents in “enriched” populations are: 1) the
otential for “creep” back toward placebo event rates in a
oninferiority trial design; and 2) the need to develop
erformance boundaries to define noninferiority in an “en-
iched” population not previously systematically studied
sing the active control therapy (26–29). Both issues may be
ddressed by the development of an imputed-placebo-
elative-risk boundary. The techniques for creating indirect
omparisons of a new treatment to placebo have been
escribed (29). Using these methods it is possible to
stimate how the experimental drug-eluting stent will per-
orm versus placebo if a placebo were present. For example,
n constructing a comparative study that uses the TAXUS
tent in a multivessel population (not studied in the
AXUS-IV trial), the primary clinical end point in the
xperimental drug-eluting stent arm would be compared
ith the TAXUS arm using relative risk as a measure
ecause the noninferiority margin (delta) can be stated in
erms of a relative risk. The imputed placebo calculations for
he trial could be based on the results of all TAXUS studies
eported, as shown in Figure 1. These results are combined
sing a random effects empirical Bayes estimator. The
ombined estimate of the relative risk for major adverse
ardiovascular events to nine months is 0.52 with 95%
onfidence limits of 0.40 to 0.67. The reciprocal of this
pper confidence limit forms a natural delta for noninferi-
rity. This delta insures that the imputed placebo relative
isk will be significantly lower than 1, indicating that the
xperimental drug-eluting stent is significantly better than
lacebo. This statistical methodology and design will likely
hart the course for future active control, noninferiority
rials of newer drug-eluting stent platforms.
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Editorial Comment April 19, 2005:1206–12UBSET ANALYSES FROM PIVOTAL TRIALS
ne must acknowledge that simple, non-prespecified sub-
roup analyses such as those described in the TAXUS-IV
ubstudy reports (only presentation of the stratified results
y vessel size and diabetes were prespecified in the
AXUS-IV trial protocol) have limited power to provide
ssurances as to safety or efficacy of a new device and are, at
est, hypothesis-generating. Furthermore, the main effect
nalysis methodology of the primary end point used for two
f these reports (left anterior descending target lesion
ocation and diabetes) essentially repeats the findings re-
orted in the primary publications (with expanded second-
ry end point analysis) showing a similar positive treatment
ffect as in the overall TAXUS subject sample (10,30).
hat is absent from these multiple subgroup analyses is a
omparison of treatment effect between complementary
ubsets (i.e., a test of interaction) (31). Because these subsets
re concluded to have similar outcomes as the overall
andomized cohort, an estimation of the power to detect a
iven difference in treatment effect would help to put the
ndings into perspective.
Evidence of generalizability for treatment effect across
ubgroups of interest should be addressed in the initial trial
esign, with special attention to eligibility criteria, rather
han reliance on subgroup analyses from an already positive
tudy. Any added value in showing similarity of treatment
ffect among subgroups is limited by both statistical power
type 2 error) and multiple comparisons (type 1 error) (32).
ubset analyses, always done with a test for interaction
hould be reserved for subgroups suspected of having a
ifferential treatment effect, and this suspected difference
hould be quantified and prespecified.
Nevertheless, for patients with treated diabetes, the
AXUS stent appears relatively safe and effective for reduc-
ng clinical or angiographic restenosis in comparison to the
are-metal EXPRESS-2 stent platform. Furthermore, the
igure 1. Relative risk for major adverse cardiovascular events (MACE) up
o nine months in randomized trials of the TAXUS paclitaxel-eluting
tent; MACE is composite occurrence of cardiovascular death, myocardial
nfarction, or target vessel revascularization (see text). MR  moderate
elease; SR  slow release.agnitude of TAXUS benefit (vs. EXPRESS-2) does not (ppear different by diabetic treatment (insulin vs. oral
gents) (13). Similarly, the subgroup analysis of patients
ndergoing TAXUS stent deployment for left anterior
escending coronary artery stenosis reported by Dangas et
l. (14) supports the relative safety and efficacy of TAXUS
ompared with the EXPRESS-2 stent. In addition, the
nalysis of gender-based outcomes for TAXUS versus
XPRESS-2 stent deployment presented by Lansky et al.
15) supports the relative safety and efficacy of TAXUS.
inally, an analysis of patients classified as having an acute
oronary syndrome (unstable angina or non–ST-segment
levation myocardial infarction) demonstrates the salutary
ffects of TAXUS compared with EXPRESS-2 stent de-
loyment for reducing angiographic and clinical restenosis
s well as major adverse cardiovascular events (16). Al-
hough 20% of patients classified as having an acute coro-
ary syndrome in the TAXUS-IV trial had non–ST-
egment elevation myocardial infarction, angiographically
emonstrable thrombus was an exclusion from enrollment
nto this trial (10). Surprisingly, two-thirds of patients
nrolled into the TAXUS-IV trial had a history of angina
ectoris at rest. Unfortunately, these underpowered analyses
o not provide definitive evidence from which conclusive
tatements regarding safety and efficacy in the populations
tudied can be made. Similar limitations are applicable to
rior subgroup analyses reported from the SIRIUS trial
33,34).
ENSION BETWEEN PROOF OF
RINCIPLE AND GENERALIZABILITY
ew technologies require first evaluation under controlled,
lmost experimental conditions that emphasize validity and
roof of principle. Such trials aim to reduce confounding
esign features by using uncomplicated subjects and simple
nd points. Once proof of principle is validated, trials that
mphasize broader clinical application and generalizability
ay relax the “experimental” conditions, and test the new
echnology on more complex patient cohorts using more
ractical clinical outcomes. Unfortunately, the burden of
eneralizability has previously been relegated largely to
ost-market studies, which have been less effective than
esired.
As experience with drug-eluting stent and clinical prac-
ice expands, the landscape for clinical trial evaluation of
ew drug-eluting stent platforms is rapidly evolving. Thus,
wo clinical trial methodologies emerge. For first- or
econd-in-class experimental therapies, the pivotal trial
ethod used in the TAXUS-IV and SIRIUS randomized
rials, where emphasis is placed on validation and mecha-
ism of action and which requires protocol-driven invasive
valuation in a prespecified portion of patients will be
mployed. This pivotal trial format will comprise a sample
ize of 1,000 to 2,000 randomized patients and will likely
ncorporate a subset in which several surrogate end points
such as late loss) are measured. These powerful continuous
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April 19, 2005:1206–12 Editorial Commentngiographic measures will also likely have been employed
n smaller preliminary studies used to screen out ineffective
herapies or test new doses before initiating larger random-
zed trial evaluations.
As an experimental therapy becomes standard-of-care, a
econd trial method with a trial sample that more closely
pproximates the target population will be employed. Thus,
shift from an evaluation methodology aimed at proof of
oncept with multiple surrogate end points, obtained by
nvasive techniques in a relatively low-risk patient sample, to
n evaluation methodology that employs more clinically
elevant end points in a higher-risk “enriched” patient
ohort will occur. As the noninferiority active control trial
ethodology becomes dominant, methods to assure preven-
ion of recession to mediocrity, or “placebo creep” back to a
reatment effect no better than “placebo” (i.e., bare-metal
tent) standard, must be utilized (26–29).
UMMARY
he TAXUS-IV trial reports and accompanying commen-
ary provide several global perspectives that are pertinent to
ll drug-eluting stents as well as strategies for future
rug-eluting stent evaluation. First, drug-eluting stent plat-
orms elicit a biologic response with respect to angiographic
ate coronary lumen loss that differs in its distribution from
he late loss distribution previously observed in response to
are-metal stent deployment. The precedent statistical
ethodology used to describe this response and its relation-
hip to restenosis is no longer accurate. Late loss retains a
lose correlation with late outcomes when appropriate
tatistical methodology is applied. Thus, the “game” (im-
ortance of late loss) remains the same in the era of
rug-eluting stent; only the “rules” (statistical methodology)
ave changed. Therefore, we might predict that in a
andomized comparative trial of two drug-eluting stents
ith differing levels of late loss, if reference vessel diameter
nd post-procedural gains are equivalent, late loss will
emain a valuable and ordinal variable directly related to
dverse late clinical events including restenosis. Second, the
ecent focus on angiographic “surrogate” end points need
ot blind us to the importance of meaningful clinical
utcomes. Although angiographic end points may be
dopted to screen therapies for effectiveness, they have
imited ability to detect unusual but important events such
s stent thrombosis. Furthermore, the challenges of “real”
linical practice (multivessel and complex subset interven-
ion) will likely exaggerate differences in clinical outcomes
ssociated with specific drug-eluting stent platforms. Third,
he practice of underpowered post-hoc subgroup analyses
rom pivotal trials offers limited assurance of device safety or
fficacy in a relatively well-circumscribed “lower-risk” cohort
han would be treated in routine clinical practice. These
nalyses must not take the place of larger randomized
linical trials which, in turn, may be supplemented by more
omprehensive and complete registry data. Finally, we maye forced to consider alternative algorithms for new device
esting and approval that could incorporate more rigorous
nd comprehensive post-market surveillance evaluation to
oth assure patient safety and yet (hopefully) facilitate the
re-market approval process.
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